MedTrace Logo

Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients

NCT03528421 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-07-16

No results posted yet for this study

Summary

n this study, approximately 30 patients with relapsed or refractory non-Hodgkin's lymphoma (NHL) were recruited for a single reinfusion of IM19-CD28 and IM19-41BB CAR-T cells. Assess the safety, tolerability of treatment, and initially observe the efficacy.

Conditions

  • Non Hodgkin Lymphoma

Interventions

BIOLOGICAL

IM19

CAR-T cells

DRUG

Fludarabine

Two days before cell infusion, all patients will be treated with fludarabine for 3 days

DRUG

Cyclophosphamide

Two days before cell infusion, all patients will be treated with Cyclophosphamide for 3 days

Sponsors & Collaborators

  • Peking University Cancer Hospital & Institute

    collaborator OTHER

  • Beijing Immunochina Medical Science & Technology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2020-04-30
Completion
2020-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03528421 on ClinicalTrials.gov